Partner Content Partner Content VIDEO: Immunotherapy monitoring: Is Immuno-PET the solution? The rapid advancement of immunotherapy in recent years has presented a number of challenges to pharmaceutical firms looking to monitor and measure efficacy in patients.
News BMS and Nektar to pair Opdivo with natural killer cell drug BMS and Nektar's combination latest in frenzied immunotherapy field
News Merck makes its move: Keytruda filed for first line lung can... Merck steals a march on rival BMS.
Views & Analysis Novartis committed to CAR-Ts - but doubts about commercial v... Novartis may have concerns about commercial prospects, says expert.
News Bavarian and BMS press on with Opdivo and cancer vaccine com... BMS hopes combinations will maintain Opdivo lead after setback
Views & Analysis Promise for combination approach to cancer As immuno-oncology increasingly involves more than one agent for best efficacy, market positioning must take a pan-tumour approach.
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.